Gufic Biosciences Share Price

Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.As of 10 Jun 2026, Gufic Biosciences share price is ₹386.80. The stock opened at ₹379.00, compared to its previous close of ₹376.70. During today's trading session, Gufic Biosciences share price moved in the range of ₹377.80 to ₹392.95, with an average price of ₹385.38 for the day. Looking at its last 52-week, the stock has touched a low of ₹377.80 and a high of ₹392.95. On the performance front, Gufic Biosciences share price has increased by 9.98% over the last six months and is up 4.65% on a year-on-year basis.

The market capitalization of Gufic Biosciences is ₹3,774 Crs, with a P/E ratio of 58.8 and a dividend yield of 0.00%.